Assetmark Inc. Has $5.11 Million Position in Bio-Rad Laboratories, Inc. $BIO

Assetmark Inc. increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 131.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,175 shares of the medical research company’s stock after buying an additional 12,023 shares during the quarter. Assetmark Inc.’s holdings in Bio-Rad Laboratories were worth $5,110,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in Bio-Rad Laboratories by 3,633.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock worth $27,000 after buying an additional 109 shares in the last quarter. Quarry LP acquired a new stake in Bio-Rad Laboratories during the first quarter worth approximately $29,000. Allworth Financial LP grew its position in Bio-Rad Laboratories by 260.0% during the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock worth $36,000 after buying an additional 104 shares in the last quarter. UMB Bank n.a. grew its position in Bio-Rad Laboratories by 89.8% during the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock worth $40,000 after buying an additional 79 shares in the last quarter. Finally, Headlands Technologies LLC grew its position in Bio-Rad Laboratories by 64.1% during the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock worth $87,000 after buying an additional 139 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada raised their target price on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Citigroup raised their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company raised their target price on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, Weiss Ratings raised Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $358.50.

Bio-Rad Laboratories Stock Up 5.2%

Shares of BIO opened at $320.59 on Monday. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99. The stock has a market capitalization of $8.68 billion, a price-to-earnings ratio of -13.19 and a beta of 0.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.67 and a current ratio of 5.12. The stock has a fifty day moving average of $298.69 and a 200-day moving average of $265.36.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 EPS for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The firm had revenue of $653.00 million during the quarter, compared to the consensus estimate of $651.30 million. During the same quarter in the previous year, the company posted $2.01 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.